Anti‐tumor effects of TNFAIP3 were shown in B cell lymphoma, colorectal carcinoma, and hepatocellular carcinoma, but TNFAIP3 acts as an oncogene in breast cancer, gastric cancer, and melanoma.20 This evidence concerns the gene TNFAIP3 and hepatocellular carcinoma.